In general, the use of PPARγ agonists over type 2 diabetes was one of the earliest applications built upon the discovery and knowledge of PPARγ with clinical evidence as an antidiabetic agent, with approved experimental agonists including pioglitazone, rosiglitazone, and rivoglitazone [89]. This evidence concerns the gene PPARG and type 2 diabetes mellitus.